Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

L, Boiron; E, Joura; N, Largeron; B, Prager; M, Uhart

doi:10.1186/s12879-016-1483-5

Public

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

Shared by NobleBlocks on Apr 16, 2016 • 12:00 AM UTC

Authors:

Boiron L

Joura E

Largeron N

Abstract

<h4>Background</h4>HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina, anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts and recurrent respiratory papillomatis. In the context of the arrival of a nonavalent HPV vaccine (6/11/16/...

Subject

Vaccination

Cervical cancer

Austria

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!